MARC details
000 -LEADER |
fixed length control field |
02759nam a22002537a 4500 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
OSt |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20190805094529.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
190804b ||||| |||| 00| 0 eng d |
040 ## - CATALOGING SOURCE |
Transcribing agency |
MSa |
082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
547 |
100 ## - MAIN ENTRY--PERSONAL NAME |
Personal name |
Assem Mohamed Habib 154375 |
245 ## - TITLE STATEMENT |
Title |
Preparing of Cyclodextrin Polymeric Nanoparticles for Enhancing Drug Bioavailability // GP // Dr. Eman Saddar // T.A. Heidi Ayman Mahmoud (2018 - 2019) |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Place of publication, distribution, etc. |
GIZA : |
Name of publisher, distributor, etc. |
MSA, |
Date of publication, distribution, etc. |
2019. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
62 P. |
440 ## - SERIES STATEMENT/ADDED ENTRY--TITLE |
Title |
PharmaciesDISTINGUISHED PROJECTS 2019 |
500 ## - GENERAL NOTE |
General note |
Pharmacy - Organic Chemistry |
520 ## - SUMMARY, ETC. |
Summary, etc. |
Rosuvastatin calcium is one of a statin medication, used to prevent cardiovascular disease in those at<br/>high risk and treat abnormal lipids. It is a poorly soluble drug with oral bioavailability 20% due to<br/>extensive first pass effect. The study aimed to formulate cyclo-dextrin loaded polyrotaxane<br/>nanoparticles loaded with Rosuvastatin Calcium to improve its solubility, efficacy and reduce side<br/>effects. The effects of polymers (PVP), cyclodextrin concentrations or their combinations at different<br/>polymers ratios on the drug solubility dissolution rate was studied.<br/>The Experimental studies: Polyrotaxane was prepared by dissolving drug, PVP and<br/>cyclodextrane all together. The mixture was cooled for 24 hour to allow precipitation of drug-<br/>polyrotaxane powder, then dried at at 40 oC for 24 hours. The dried powdered was weighted. The drug<br/>content of polyrotaxane was determined. 0.05 g of the prepared polyrotaxane was dissolved in 10 ml<br/>methanol, to guarantee complete drug solubility. The drug concentration was measured<br/>spectrophotometrically at wavelength 243nm. The dissolution test used to compare between the poorly<br/>soluble rosuvastatin drug and polyrotaxane. Differential scanning calorimetry test used to concern with<br/>the measurement of energy acquired or emitted by a sample of matter when it is heated or cooled. It<br/>also provides information about endothermic and exothermic processes. X- Ray powder diffraction is a<br/>technique that utilizes x- ray scattering pointed on crystals of powder to give identity and information<br/>about the crystalline structure.<br/>The Results: The powder weight was 2.8gm presents 22.85 % yield. Five mg of polyrotaxane<br/>contains 3.575 mg pure drug (71.5% drug loading and 1%.encapsulation efficiency. Polyrotaxane<br/>complex enhance both drug solubility and dissolution. |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cyclodextrin Polymeric Nanoparticles |
General subdivision |
Enhancing Drug |
Chronological subdivision |
Bioavailability |
700 ## - ADDED ENTRY--PERSONAL NAME |
Personal name |
Rozana Akmal Kamal 150271 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Personal name |
Mariam Magdy Aziz 153587 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Personal name |
Salma Ahmed Khalifa 150747 |
856 ## - ELECTRONIC LOCATION AND ACCESS |
Uniform Resource Identifier |
<a href="https://drive.google.com/file/d/1bvtCdkpfdcizPa25GxUESFBJs8XY4kcg/view">https://drive.google.com/file/d/1bvtCdkpfdcizPa25GxUESFBJs8XY4kcg/view</a> |
Public note |
FULL TEXT PRESS HERE |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Source of classification or shelving scheme |
Dewey Decimal Classification |
Koha item type |
Distinguished Graduation Projects |